STOCK TITAN

ANI Pharmaceuticals to Discuss Second Quarter 2021 Financial Results on August 6, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
earnings

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2021 financial results on Friday, August 6, 2021.

Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows:

Date

Friday, August 6, 2021

Time

8:30 a.m. ET

Toll free (U.S.)

866-342-8591

Webcast (live and replay)

www.anipharmaceuticals.com, under the “Investors” section

A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for one-week by dialing 800-695-0974 and entering access code 5412658.

About ANI

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. We focus on niche and high barrier to entry opportunities including controlled substances, oncology products (anti-cancers), hormones and steroids, and complex formulations. For more information, please visit our website www.anipharmaceuticals.com.

ANI Pharmaceuticals Inc

NASDAQ:ANIP

ANIP Rankings

ANIP Latest News

ANIP Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Other, Manufacturing, Biological Product (except Diagnostic) Manufacturing
US
Baudette

About ANIP

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.